Teniposide Injection

Mechanism of action: This product is a cycle-specific cytotoxic drug that acts in the late S2 and G2 phases of the cell cycle and works by preventing cells from entering mitosis. This product also causes single-strand and double-strand breaks in DNA bonds (Clark, 1987), and its mechanism of action seems to be due to the inhibition of topoisomerase II. For experimental mouse tumors, teniposide has a broad spectrum of anti-tumor activity in vivo, including a variety of hematological tumors and various solid tumors. In vitro and in vivo studies have shown that etoposide-resistant cell lines have complete cross-resistance to this product, and vice versa, but occasional clinical reports indicate that there is a lack of complete cross-resistance to the two drugs. Pharmacokinetics (Clark, 1987; O'Dwyer, 1984; Holthuis. 1987) Action characteristics: This product is a neutral lipophilic substance that can pass through the blood-brain barrier.

The main ingredient of this product is teniposide. This drug contains the following ingredients: 300 mg of N, N-dimethylacetamide, 150 mg of benzyl alcohol, 2.5 g of polyoxyethyl castor oil, 42.7% of anhydrous ethanol, and maleic acid is used to adjust the pH value

This drug is a neutral lipophilic substance, almost insoluble in water, but soluble in organic solvents. This product is a light yellow to yellow clear solution.

This product is suitable for the treatment of the following diseases, usually in combination with other anticancer drugs: malignant lymphoma; Hodgkin's disease; acute lymphocytic leukemia, high-risk cases in adults and children; intracranial malignancies: glioblastoma, vascular dysplasia, astrocytoma; bladder cancer; neuroblastoma and other solid tumors in children.

Monotherapy: The total dose of each course of treatment is 300 mg/m2 given over 3-5 days. A course of treatment can be repeated every three weeks or after the bone marrow recovers. Combination therapy: This product can be used in combination with several other approved chemotherapy drugs. When used in combination with other bone marrow suppressive drugs, the dose of this product should be appropriately reduced. Peripheral blood counts should be monitored regularly, and bone marrow examinations should be performed regularly when necessary. Note: Patients with Down syndrome are particularly sensitive to bone marrow suppressive chemotherapy (Blatr, 1986). Therefore, a reduction in dosage should be considered for these patients. Course of treatment: Generally, 4-6 courses of treatment are repeated according to the doctor's advice.

The main toxicity of this product is bone marrow suppression, which manifests as thrombocytopenia, while the decrease in white blood cells is milder. Common adverse reactions include nausea, vomiting, hair loss, diarrhea, abdominal pain, rash, fever and phlebitis, and occasional increase in transaminase. There are also reports that allergic reactions may occur with the use of this product, causing bronchospasm, skin flushing and urticaria, dyspnea and hypotension. Stomatitis, headache and mental confusion are rare.

Patients with a history of allergy to this product are contraindicated. Patients with severe leukopenia or thrombocytopenia are contraindicated.

Since anticonvulsants such as phenobarbital and phenytoin can increase the clearance of teniposide, the duration of action of a given dose of the drug in the body may be shortened (Baker.1992). For patients receiving anticonvulsant treatment, the dose of teniposide may need to be increased. It has been observed that tolbutamide, sodium salicylate, and sulfamethoxazole can displace teniposide bound to plasma proteins in vitro. (Gaver,1990) Since teniposide has a very high protein binding rate, a small reduction in the protein-bound drug can lead to a significant increase in the free drug, thereby enhancing the drug's effect and toxicity.

Store below 25°C.

5 ml: 50 mg